Molecule News and Research

RSS

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Study identifies four genetic variants associated with ESRD disease in Chinese diabetic patients

Examination of a gene involved in cell signaling finds that four common variants of this gene are associated with the development of end-stage renal disease in Chinese patients with type 2 diabetes, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Increasing levels of neuropeptide Y, receptors can counteract seizures: Research

Research in recent years has shown that the brain tries to counteract seizures. One of the ways it does this is by increasing levels of a protein-like molecule called neuropeptide Y and the expression of certain receptors for it.

25 Aug 2010

Researchers develop high-resolution technology to visualize individual virus particles

In the war against infectious disease, identifying the culprit is half the battle. Now, research professor Shaopeng Wang and his colleagues from the Biodesign Institute at Arizona State University, describe a new method for visualizing individual virus particles. Their research opens the door to a more detailed understanding of these minute pathogens, and may further the study of a broad range of micro- and nanoscale phenomena.

25 Aug 2010

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Research on OGF-OGFr complex helps to understand pathobiology of diseases

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.

24 Aug 2010

Scientists develop nano-sized vehicle to deliver chemotherapy drugs directly into cancer cells

Chemotherapy, while an effective cancer treatment, also brings debilitating side effects such as nausea, liver toxicity and a battered immune system.Now, a new way to deliver this life-saving therapy to cancer patients getting straight to the source of the disease.

24 Aug 2010

Researchers find new way to study oncogene's role in DNA repair

A key step in understanding the origins of familial breast cancer has been made by two teams of scientists at the University of California, Davis. The researchers have purified, for the first time, the protein produced by the breast cancer susceptibility gene BRCA2 and used it to study the oncogene's role in DNA repair.

23 Aug 2010

Hospira Japan receives approval for long term use of Precedex IV sedative

Hospira Japan Co., Ltd. today announced it has received an approval for the long-term (greater than 24 hour) use of the sedative "Precedex IV™200ug" (generic name: dexmedetomidine hydrochloride). This approval follows Hospira's first launches earlier this year of Precedex in Canada and in South Korea, important milestones for Hospira as the company continues to build the molecule's global presence.

23 Aug 2010

ChemAxon adds more predictions to chemistry browsing service

ChemAxon announces the addition of major new functionality in it's chemicalize.org web based service. The new features help users understand better the chemical structure with more predicted properties and a customizable layout to be of most use.

21 Aug 2010

Researchers develop tiny color-changing sensor molecules

A new approach to building an "artificial nose" using fluorescent compounds and DNA could accelerate the use of sniffing sensors into the realm of mass production and widespread use, say Stanford chemists. If their method lives up to its promise, it could one day detect everything from incipiently souring milk to high explosives.

21 Aug 2010

New squeeze test for screening potential drugs for Alzheimer's

Brain cells exposed to a form of the amyloid beta protein, the molecule linked to Alzheimer's disease, become stiffer and bend less under pressure, researchers at UC Davis have found. The results reveal one mechanism by which the amyloid protein damages the brain, a finding that could lead to new ways to screen drugs for Alzheimer's and similar diseases.

21 Aug 2010

'Rotten eggs' gas inside knee joint protects against inflammation

Hydrogen sulfide (H2S) is a gas more commonly associated with the smell of 'rotten eggs' and blocked drains. However, it has now been shown to be present naturally in our bodies and reside in knee joint synovial fluid, the protective fluid found in the cavities of joints that reduces friction between the cartilage of joints during movement. Synovial fluid H2S may play a role in reducing inflammation in joints.

21 Aug 2010

Research on ocean-dwelling bacterium unveils food poisoning mechanism in human

Researchers at UT Southwestern Medical Center have uncovered a key weapon in the molecular arsenal the infectious bacterium Vibrio parahaemolyticus (V. para) uses to kill cells and cause food poisoning in its human host.

20 Aug 2010

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

International Stem Cell Corporation, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™.

20 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $228,668 to Cognition Therapeutics (CogRx) to develop small molecule drugs that block the action of the toxic "oligomers" thought responsible for Alzheimer's disease (AD).

19 Aug 2010

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures.

19 Aug 2010

Gene-regulating molecule plays key role in development of Th9 cells linked to chronic respiratory tract illness

Scientists at the University Medical Center of Johannes Gutenberg University Mainz, Germany have taken a further step towards improving our understanding of how asthma develops. These new findings show that the gene-regulating molecule "IRF4" plays a key role in the development of T helper 9 lymphocytes (Th9 cells), which can play a major part in the development of this chronic, inflammatory illness of the respiratory tract.

18 Aug 2010

Molecule News and Research

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Study identifies four genetic variants associated with ESRD disease in Chinese diabetic patients

Increasing levels of neuropeptide Y, receptors can counteract seizures: Research

Researchers develop high-resolution technology to visualize individual virus particles

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Research on OGF-OGFr complex helps to understand pathobiology of diseases

Scientists develop nano-sized vehicle to deliver chemotherapy drugs directly into cancer cells

Researchers find new way to study oncogene's role in DNA repair

Hospira Japan receives approval for long term use of Precedex IV sedative

ChemAxon adds more predictions to chemistry browsing service

Researchers develop tiny color-changing sensor molecules

New squeeze test for screening potential drugs for Alzheimer's

'Rotten eggs' gas inside knee joint protects against inflammation

Research on ocean-dwelling bacterium unveils food poisoning mechanism in human

ISCO to formalize eye care based stem cell therapeutic programs into Cytovis business unit

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Cognition Therapeutics receives grant to develop small-molecule drug candidate for Alzheimer's disease

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

Gene-regulating molecule plays key role in development of Th9 cells linked to chronic respiratory tract illness

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News